A plant-based COVID-19 vaccine from a GlaxoSmithKline alliance with Medicago shows strong antibody response
Trial participants have 10 times more antibodies in their systems than patients recovering from COVID-19 Picture: Vials on a production line at a GSK factory that will be used in the collaboration with Canada’s Medicago. FRANCOIS LO PRESTI/AGENCE FRANCE-PRESSE/GETTY IMAGES Pharmaceutical giant GlaxoSmithKline GSK, -0.70% and Canadian vaccine maker Medicago have reported promising results from a Phase 2 clinical trial …